natgillin/translations-raw huggingface dataset:
Moreover, at concentrations substantially higher (approximately 300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug metabolism mediated by any of the major human CYP450 isoforms involved in drug biotransformation (CYP3A4, CYP2D6, CYP2C9, CYP2E1, or CYP1A1/2). 
Nadalje tenofovir pri koncentracijah, znatno višjih (približno 300-krat) od tistih, ki so jih opazili in vivo, in vitro ni zaviral presnavljanja zdravil, pri katerem posreduje katera koli od pomembnejših izooblik glavnega humanega CYP450, ki sodelujejo pri biotransformaciji (CYP3A4, CYP2D6, CYP2C9, CYP2E1 ali CYP1A1/2).
• and you notice 18 hours or more after the time you usually take Stribild, then do not take the missed dose. 
• in to opazite po 18 urah ali več od časa, ko običajno vzamete zdravilo Stribild, pozabljenega odmerka ne vzemite.
Exposures of cobicistat and emtricitabine in paediatric patients aged 12 to <18 years were similar to exposures achieved in adults. 
Izpostavljenosti kobicistatu in emtricitabinu so bile pri pediatričnih bolnikih, starih od 12 do < 18 let, podobne kot izpostavljenosti, dosežene pri odraslih.
It is important not to miss a dose of Stribild. 
Pomembno je, da ne pozabite vzeti nobenega odmerka zdravila Stribild.
The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited. 
Farmakokinetičnih lastnosti emtricitabina niso proučevali pri osebah z jetrno okvaro, vendar jetrni encimi emtricitabina ne presnavljajo v pomembnem obsegu, zato je vpliv jetrne okvare verjetno omejen.
Based on drug interaction studies conducted with the components of Stribild, no clinically significant drug interactions have been either observed or are expected between the components of Stribild and the following medicinal products: entecavir, famciclovir, famotidine, omeprazole, ribavirin and sertraline. 
Na podlagi študij medsebojnega delovanja z zdravilom, opravljenih z učinkovinami zdravila Stribild, klinično pomembnih interakcij med učinkovinami zdravila Stribild in naslednjimi zdravili bodisi niso opazili ali jih ni pričakovati: entekavir, famciklovir, famotidin, omeprazol, ribavirin in sertralin.
The use of Stribild in children below 12 years of age and who weigh less than 35kg has not been studied. 
Uporabe zdravila Stribild pri otrocih, starih manj kot 12 let, ki tehtajo manj kot 35 kg, še niso preučili.
Elvitegravir plasma concentrations are lower with antacids due to local complexation in the gastrointestinal tract and not to changes in gastric pH. 
Koncentracije elvitegravirja v plazmi so z antacidi nižje zaradi lokalne kompleksacije v prebavilih in ne zaradi sprememb vrednosti pH v želodcu.
Cobicistat is also a weak CYP2D6 inhibitor and is metabolised, to a minor extent, by CYP2D6. 
Kobicistat je tudi šibak zaviralec CYP2D6, ki ga v manjšem obsegu presnavlja CYP2D6.
While taking Stribild you may still develop infections or other illnesses associated with HIV infection. 
Med jemanjem zdravila Stribild se lahko pojavijo okužbe ali druge bolezni, povezane z okužbo z virusom HIV.
However, patients should be informed that dizziness, fatigue and insomnia have been reported during treatment with Stribild. 
Vendar je bolnike potrebno opozoriti, da se lahko v času zdravljenja z zdravilom Stribild pojavijo omotičnost, utrujenost in nespečnost.
Two of the four subjects had renal impairment (i.e. estimated creatinine clearance less than 70 mL/min) at baseline. 
2 od 4 oseb sta imeli na začetku ledvično okvaro (tj. ocenjeni očistek kreatinina manj kot 70 ml/min).
hypokalaemia1,3 
hipokaliemija1,3
Therefore, information regarding drug-drug interactions with other antiretroviral products (including protease inhibitors and non-nucleoside reverse transcriptase inhibitors) is not provided (see section 4.4). 
Zato informacije o medsebojnem delovanju z drugimi protiretrovirusnimi zdravili (vključno z zaviralci proteaze in nenukleozidnimi zaviralci reverzne transkriptaze) niso na voljo (glejte poglavje 4.4).
Table 5: Changes in pharmacokinetic parameters from the IMPAACT P1026s study for elvitegravir and cobicistat in women receiving cobicistat and elvitegravir-containing regimens during the second and third trimesters of pregnancy compared to paired postpartum data 
Preglednica 5: Spremembe farmakokinetičnih parametrov iz študije IMPAACT P1026s za elvitegravir in kobicistat pri ženskah, ki so prejemale režime s kobicistatom in elvitegravirjem v drugem in tretjem trimestru nosečnosti, v primerjavi s sparjenimi podatki iz poporodnega obdobja
The safety and efficacy of Stribild in children under the age of 12 years have not been established (see section 4.2 for information on paediatric use). 
Varnost in učinkovitost zdravila Stribild pri otrocih, starih manj kot 12 let, še nista bili dokazani (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
In patients at risk for renal impairment a more frequent monitoring of renal function is required. 
Pri bolnikih s tveganjem za ledvično okvaro je treba ledvične funkcije nadzirati pogosteje.
• gastrointestinal motility agents: cisapride 
• učinkovine za gastrointestinalno gibljivost: cisaprid
At week 48, six adolescents in the tenofovir disoproxil group and one adolescent in the placebo group had significant lumbar spine BMD loss (defined as > 4% loss). 
V 48. tednu so imeli šest mladostnikov v skupini z dizoproksiltenofoviratom in en mladostnik v skupini s placebom pomembno zmanjšanje BMD ledvene hrbtenice (opredeljeno kot zmanjšanje > 4 %).
Following intravenous administration the volume of distribution of emtricitabine and tenofovir was approximately 1,400 mL/kg and 800 mL/kg, respectively. 
Po intravenskem odmerku je volumen porazdelitve emtricitabina znašal približno 1.400 ml/kg in volumen porazdelitve tenofovirja približno 800 ml/kg.
If you accidentally take more than the recommended dose of Stribild you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects). 
Če ste pomotoma zaužili odmerek zdravila Stribild, višji od priporočenega, obstaja povečano tveganje za pojav možnih neželenih učinkov (glejte poglavje 4, Možni neželeni učinki).
In a human clinical study of 35 healthy subjects, echocardiograms performed at baseline and after receiving 150 mg cobicistat once daily for at least 15 days indicated no clinically significant change in left ventricular function. 
V klinični študiji pri človeku s 35 zdravimi osebami ehokardiogrami, opravljeni ob začetku in po vsaj 15-dnevnem prejemanju 150 mg kobicistata enkrat dnevno ne kažejo klinično značilnih sprememb delovanja levega prekata.
Emtricitabine and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. 
Emtricitabin in tenofovir se primarno izločata preko ledvic s kombinacijo glomerularne filtracije in aktivne tubularne sekrecije.
It is recommended that Stribild is not initiated in patients with creatinine clearance < 90 mL/min unless, after review of the available treatment options, it is considered that Stribild is the preferred treatment for the individual patient. 
Priporoča se, da se zdravljenja z zdravilom Stribild pri bolnikih z očistkom kreatinina < 90 ml/min ne uvede, razen če se po pregledu vseh razpoložljivih možnosti zdravljenja ugotovi, da je zdravilo Stribild za posamičnega bolnika najboljša možnost.
When administering with Stribild, the maximum daily dose of ketoconazole should not exceed 200 mg per day. 
Pri dajanju z zdravilom Stribild največji dnevni odmerek ketokonazola ne sme preseči 200 mg dnevno.
Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any adult with renal impairment treated with Stribild (see sections 4.2, 4.4 and 5.2). 
Ker lahko dizoproksiltenofovirat povzroči ledvično toksičnost, se priporoča skrbno nadziranje ledvične funkcije pri vseh odraslih bolnikih z ledvično okvaro, ki se zdravijo z zdravilom Stribild (glejte poglavja 4.2, 4.4 in 5.2).
The mean rate of BMD gain was less in the tenofovir disoproxil group compared to the placebo group. 
Povprečna stopnja povečanja BMD je bila manjša v skupini z dizoproksiltenofoviratom v primerjavi s skupino s placebom.
Patients co-infected with HIV and HBV who discontinue Stribild should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. 
Bolnike s hkratno HIV in HBV okužbo, ki prekinejo zdravljenje z zdravilom Stribild, je potrebno pozorneje opazovati in opraviti potrebne klinične in laboratorijske teste še vsaj nekaj mesecev po prenehanju zdravljenja.
Following oral administration of Stribild with food in HIV-1 infected subjects, peak plasma concentrations were observed 4 hours post-dose for elvitegravir, 3 hours post-dose for cobicistat, 3 hours post-dose for emtricitabine, and 2 hours for tenofovir following the rapid conversion of tenofovir disoproxil. 
Po peroralnem dajanju zdravila Stribild s hrano osebam, okuženim z virusom HIV-1, so najvišje plazemske koncentracije opazili 4 ure po odmerku za elvitegravir, 3 ure po odmerku za kobicistat, 3 ure po odmerku za emtricitabin in 2 uri po odmerku za tenofovir po hitri konverziji dizoproksiltenofovirata.
Cobicistat exposures were unaffected by a light meal and although there was a modest decrease of 24% and 18% in Cmax and AUC respectively with a high-fat meal, no difference was observed in its pharmacoenhancing effect on elvitegravir. 
Lahek obrok ni vplival na izpostavljenost kobicistata in čeprav je bilo pri obroku z visoko vsebnostjo maščobe vidno zmerno zmanjšanje Cmax za 24 % in AUC za 18 %, razlike v učinku farmakokinetične krepitve elvitegravirja niso opazili.
hyperglycaemia1, hypertriglyceridaemia1, decreased appetite 
hiperglikemija1, hipertrigliceridemija1, zmanjšan apetit
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to desacetyl-rifabutin. 
Utemeljeno je povečano spremljanje neželenih učinkov, povezanih rifabutinom, vključno z nevtropenijo in uveitisom, zaradi pričakovane večje izpostavljenosti desacetil-rifabutinu.
Three (0.8%) subjects who received ATV/r+FTC/tenofovir disoproxil developed laboratory findings consistent with proximal renal tubular dysfunction leading to discontinuation of ATV/r+FTC/tenofovir disoproxil after Week 96 (see section 4.4). 
Tri osebe (0,8 %), ki so prejemale ATV/r+FTC/dizoproksiltenofovirat, so imele laboratorijske izsledke, skladne z disfunkcijo zaradi proksimalne ledvične tubulopatije, kar je povzročilo prekinitev uporabe ATV/r+FTC/dizoproksiltenofovirata po 96 tednih (glejte poglavje 4.4).
Stribild is indicated for use as a complete regimen for the treatment of HIV-1 infection and must not be administered with other antiretroviral products. 
Zdravilo Stribild je indicirano za uporabo kot celovit režim zdravljenja okužbe z virusom HIV-1 in se ne sme dajati skupaj z drugimi protiretrovirusnimi zdravili.
The use of Stribild with oral contraceptives containing other progestogens should be avoided (see section 4.5). 
Uporabi zdravila Stribild s peroralnimi kontraceptivi, ki vsebujejo druge progestogene, se je treba izogniti (glejte poglavje 4.5).
Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Stribild with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products. 
Ker se emtricitabin in tenofovir izločata predvsem preko ledvic, sočasna uporaba zdravila Stribild in zdravil, ki zmanjšujejo ledvično funkcijo ali tekmujejo za aktivno tubularno sekrecijo (npr. cidofovir), lahko poveča serumske koncentracije emtricitabina, tenofovirja in/ali sočasno uporabljenih zdravil.
Resistance to emtricitabine or tenofovir has been seen in vitro and in the HIV-1 from some patients due to the development of the M184V or M184I emtricitabine resistance substitution in reverse transcriptase or the K65R tenofovir resistance substitution in reverse transcriptase. 
Rezistenca na emtricitabin ali tenofovir je bila opažena in vitro in pri HIV-1 nekaterih bolnikov zaradi razvoja substitucije M184V ali M184I reverzne transkriptaze, povezane z rezistenco na emtricitabin, ali substitucije K65R reverzne transkriptaze, povezane z rezistenco na tenofovir.
Exposures of elvitegravir and tenofovir in paediatric patients aged 12 to <18 years who received Stribild in GS-US-236-0112 were increased by 30% and 37% respectively, when compared with historical adult controls. 
Izpostavljenosti elvitegravirju in tenofovirju pri pediatričnih bolnikih, starih od 12 do < 18 let, ki so prejemali zdravilo Stribild v študiji GS-US-236-0112, so se povečale za 30 % oz. 37 % v primerjavi z zgodovinsko kontrolno skupino z odraslimi bolniki.
For the treatment of erectile dysfunction, it is recommended that a single dose of sildenafil no more than 25 mg in 48 hours, vardenafil no more than 2.5 mg in 72 hours, or tadalafil no more than 10 mg in 72 hours be co-administered with Stribild. 
Za zdravljenje erektilne disfunkcije se pri sočasni uporabi z zdravilom Stribild priporoča enkratni odmerek sildenafila največ 25 mg v 48 urah, vardenafila največ 2,5 mg v 72 urah ali tadalafila največ 10 mg v 72 urah.
The pharmacokinetics of elvitegravir or cobicistat in paediatric subjects <12 years of age have not been fully established. 
Farmakokinetične lastnosti elvitegravirja ali kobicistata pri pediatričnih bolnikih < 12 let starosti niso v celoti ugotovljene.
There are currently inadequate data to determine whether co-administration of tenofovir disoproxil and cobicistat is associated with a greater risk of renal adverse reactions compared with regimens that include tenofovir disoproxil without cobicistat. 
Trenutno ni dovolj podatkov, da bi ugotovili, ali je sočasna uporaba dizoproksiltenofovirata in kobicistata povezana z večjim tveganjem za neželene učinke na ledvice, v primerjavi z režimi, ki vključujejo dizoproksiltenofovirat brez kobicistata.
The safety and efficacy of Stribild in children under the age of 12 years or weighing < 35 kg have not been established (see section 5.2). 
Varnost in učinkovitost zdravila Stribild pri otrocih, starih manj kot 12 let ali ki tehtajo manj kot < 35 kg, nista bili dokazani (glejte poglavje 5.2).
In phenotypic analyses of isolates from patients in the resistance analysis population, 13 patients (31%) had HIV-1 isolates with reduced susceptibility to elvitegravir, 17 patients (40%) had reduced susceptibility to emtricitabine, and 2 patients (5%) had reduced susceptibility to tenofovir. 
V fenotipskih analizah izolatov bolnikov populacije za analizo rezistence je imelo 13 bolnikov (31 %) izolate HIV-1 z zmanjšano občutljivostjo na elvitegravir, 17 bolnikov (40 %) je imelo izolate HIV-1 z zmanjšano občutljivost na emtricitabin in 2 bolnika (5 %) sta imela izolate HIV-1 z zmanjšano občutljivost na tenofovir.
digoxin, disopyramide, flecainide, lidocaine, mexiletine, propafenone, metoprolol, timolol, amlodipine, diltiazem, felodipine, nicardipine, nifedipine and verapamil 
• zdravila za srce, kot so: digoksin, disopiramid, flekainid, lidokain, meksilitin, propafenon, metoprolol, timolol, amlodipin, diltiazem, felodipine, nikardipin, nifedipin in verapamil
As elvitegravir and cobicistat are highly bound to plasma proteins it is unlikely that elvitegravir and cobicistat will be significantly removed by haemodialysis or peritoneal dialysis. 
Ker se elvitegravir in kobicistat močno vežeta na plazemske proteine, ni verjetno, da bi hemodializa ali peritonealna dializa elvitegravir in kobicistat odstranila v pomembni meri.
Midazolam and triazolam are primarily metabolised by CYP3A. 
Midazolam in triazolam presnavlja pretežno CYP3A.
elevated creatine kinase1 
povišana kreatin kinaza1
In vitro protein binding of tenofovir to plasma or serum protein was less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 µg/mL. 
In vitro je bila vezava tenofovirja na plazemske proteine manjša od 0,7% oziroma na serumske proteine manjša od 7,2 % v koncentracijskem območju tenofovirja od 0,01 do 25 µg/ml.
All 48 patients who received at least one dose of Stribild remained suppressed (HIV-1 RNA < 50 copies/mL) through Week 48. 
Vseh 48 bolnikov, ki so prejeli vsaj en odmerek zdravila Stribild, je ostalo supresiranih (HIV-1 RNA < 50 kopij/ml) do vključno konca 48. tedna.
If the patient misses a dose of Stribild within 18 hours of the time it is usually taken, the patient should take Stribild with food as soon as possible and resume the normal dosing schedule. 
Če bolnik izpusti odmerek zdravila Stribild v roku 18 ur od časa, ko ga običajno vzame, naj bolnik vzame zdravilo Stribild s hrano takoj, ko je mogoče, nato pa nadaljuje z običajnim režimom odmerjanja.
The most frequently reported adverse reactions to Stribild in clinical studies through 48 weeks in virologically-suppressed adult patients were nausea (3% to 5%) and fatigue (6%). 
Najpogostejša neželena učinka zdravila Stribild v kliničnih študijah do vključno 48. tedna pri odraslih bolnikih z virusno supresijo sta bila navzea (3 % do 5 %) in utrujenost (6 %).
neutropenia1 
nevtropenija1
Creatinine clearance, serum phosphate, urine glucose and urine protein should be monitored every four weeks during the first year and then every three months during Stribild therapy. 
Očistek kreatinina, vrednost serumskega fosfata, koncentracije glukoze in beljakovin v urinu je treba nadzirati vsake štiri tedne v prvem letu zdravljenja in pozneje vsake tri mesece.
The safety and efficacy of Stribild have not been established in patients with significant underlying liver disorders. 
Varnost in učinkovitost zdravila Stribild nista bili ugotavljani pri bolnikih s pomembnejšimi spremljevalnimi jetrnimi motnjami.
Table 1: Interactions between the individual components of Stribild and other medicinal products 
Preglednica 1: Interakcije med posameznimi učinkovinami zdravila Stribild in drugimi zdravili Učinkovine po terapevtskih področjih
Co-administration of Stribild and sildenafil for the treatment of pulmonary arterial hypertension is contraindicated. 
Sočasno dajanje zdravila Stribild in sildenafila za zdravljenje pljučne arterijske hipertenzije je kontraindicirano.
• antibiotics, used to treat bacterial infections including tuberculosis, containing: rifabutin, clarithromycin or telithromycin 
• antibiotike, ki se uporabljajo za zdravljenje bakterijskih okužb, vključno s tuberkulozo, ki vsebujejo: rifabutin, klaritromicin ali telitromicin
Renal function (creatinine clearance and urine glucose and urine protein) should be evaluated prior to treatment initiation, and creatinine clearance, serum phosphate, urine glucose and urine protein should be monitored during treatment as in HIV-1 infected adults (see above). 
Delovanje ledvic (očistek kreatinina, glukoza v urinu in beljakovine v urinu) je treba oceniti pred uvedbo zdravljenja, med zdravljenjem pa je treba spremljati očistek kreatinina, vrednost fosfatov v serumu, glukozo v urinu in beljakovine v urinu kot pri odraslih, okuženih z virusom HIV-1 (glejte zgoraj).
Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation by UGT1A1/3 enzymes (minor route). 
Elvitegravir se presnavlja z oksidacijo s CYP3A (glavna pot) in glukuronidacijo z UGT1A1/3 (manj pomembna pot).
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as elvitegravir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism. 
Zaviranje presnove preko CYP3A s kobicistatom okrepi sistemsko izpostavljenost substratov CYP3A, kot je elvitegravir, kjer je biološka razpoložljivost omejena in razpolovna doba skrajšana zaradi presnove, odvisne od CYP3A.
Creatinine clearance should be calculated and urine glucose and urine protein should be determined in all patients. 
Izračunati je treba očistek kreatinina in določiti koncentracijo glukoze in beljakovin v urinu pri vseh bolnikih.
Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil treatment group at 144 weeks. 
Zmanjšanje BMD hrbtenice in spremembe kostnih biomarkerjev od začetne vrednosti so bile v 144 tednih pomembno večje v skupini, ki se je zdravila z dizoproksiltenofoviratom.
Green, capsule-shaped, film-coated tablet of dimensions 20 mm x 10 mm, debossed on one side with “GSI” and the number “1” surrounded by a square box on the other side. 
Zelena, kapsulne oblike, filmsko obložena tableta, z dimenzijami 20 mm x 10 mm, z vtisnjenim znakom “GSI” na eni strani in številko “1” v pravokotnem kvadratu na drugi strani.
If the patient vomits within 1 hour of taking Stribild another tablet should be taken. 
Če bolnik v roku 1 ure od jemanja zdravila Stribild bruha, naj vzame drugo tableto.
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of Stribild in pregnant women. 
Kliničnih podatkov o uporabi zdravila Stribild pri nosečnicah ni oziroma so omejeni (manj kot 300 izpostavljenih nosečnosti).
Start with the lowest possible dose of atorvastatin with careful monitoring upon co-administration with Stribild. 
Začeti je treba z najnižjim možnim odmerkom atorvastatina, ob sočasnem dajanju z zdravilom Stribild pa je potrebno skrbno spremljanje.
In vitro studies indicate that emtricitabine is not an inhibitor of human CYP450 enzymes. 
Študije in vitro kažejo, da emtricitabin ne zavira humanih encimov CYP450.
The results reported from a prospective study (IMPAACT P1026s) showed that treatment with cobicistat and elvitegravir-containing regimens during pregnancy results in lower elvitegravir and cobicistat exposures (Table 5). 
Rezultati, o katerih so poročali iz prospektivne študije (IMPAACT P1026s), so pokazali, da je zdravljenje z režimi, ki vsebujejo kobicistat in elvitegravir, med nosečnostjo povzročilo manjšo izpostavljenost elvitegravirju in kobicistatu (preglednica 5).
Twenty percent had baseline plasma HIV-1 RNA >100,000 copies/mL. 
Dvajset odstotkov je imelo ob izhodišču v plazmi RNA HIV-1 > 100.000 kopij/ml.
Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir and zidovudine. 
Virusi, odporni na emtricitabin, s substitucijo M184V/I so bili navzkrižno rezistentni na lamivudin, a so ohranili občutljivost za didanozin, stavudin, tenofovir in zidovudin.
Animal studies do not indicate harmful effects of elvitegravir, cobicistat, emtricitabine or tenofovir disoproxil on fertility. 
Študije na živalih ne kažejo škodljivih učinkov elvitegravirja, kobicistata, emtricitabina ali dizoproksiltenofovirata na plodnost.
Following oral administration of [14C]elvitegravir/ritonavir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary elimination of elvitegravir; 6.7% of the administered dose was recovered in urine. 
Po peroralni uporabi [14C]elvitegravirja/ritonavirja so 94,8 % odmerka izolirali iz blata, kar je v skladu s hepatobiliarnim izločanjem elvitegravirja; 6,7 % danega odmerka so izolirali iz urina.
• yellow skin or eyes, itching, or pain in the abdomen (tummy) caused by inflammation of the liver (hepatitis) 
• rumena obarvanost kože ali oči, srbečica, bolečine v trebuhu zaradi vnetja jeter (hepatitis)
At Week 48, 44 of 50 (88%) adolescent patients treated with Stribild achieved HIV-1 RNA <50 copies/mL and 4 achieved HIV-1 RNA ≥50 copies/mL; 1 patient discontinued study drug, and 1 had no virologic data at Week 48. 
44 od 50 (88 %) mladostnikov, zdravljenih z zdravilom Stribild, je v 48. tednu doseglo RNA HIV-1 < 50 kopij/ml in 4 so dosegli RNA HIV-1 ≥ 50 kopij/ml; 1 bolnik je prekinil zdravljenje s študijskim zdravilom in za enega ni viroloških podatkov v 48. tednu.
Do not stop taking Stribild without talking to your doctor. 
Ne prenehajte jemati zdravila Stribild, ne da bi se posvetovali z zdravnikom.